Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Previously treated recurrent CLL
Measurable lymphadenopathy
Requires therapy for CLL
Has experienced CLL progression \< 36 months since the completion of the last prior therapy
You may not be if
Recent history of a major non-CLL malignancy
Evidence of an ongoing infection
CLL refractory to bendamustine
Concurrent participation in another therapeutic clinical trial
Clareo Health | Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )
